KR20240009918A - 바이러스 감염 치료를 위한 rock2 억제제 - Google Patents

바이러스 감염 치료를 위한 rock2 억제제 Download PDF

Info

Publication number
KR20240009918A
KR20240009918A KR1020237031854A KR20237031854A KR20240009918A KR 20240009918 A KR20240009918 A KR 20240009918A KR 1020237031854 A KR1020237031854 A KR 1020237031854A KR 20237031854 A KR20237031854 A KR 20237031854A KR 20240009918 A KR20240009918 A KR 20240009918A
Authority
KR
South Korea
Prior art keywords
ring
membered
group
alkyl
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237031854A
Other languages
English (en)
Korean (ko)
Inventor
사무엘 디. 와크살
루이 우
Original Assignee
그래비톤 바이오사이언스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그래비톤 바이오사이언스 비브이 filed Critical 그래비톤 바이오사이언스 비브이
Publication of KR20240009918A publication Critical patent/KR20240009918A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237031854A 2021-02-22 2022-02-22 바이러스 감염 치료를 위한 rock2 억제제 Pending KR20240009918A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152260P 2021-02-22 2021-02-22
US63/152,260 2021-02-22
PCT/US2022/017312 WO2022178420A1 (en) 2021-02-22 2022-02-22 Rock2 inhibitor for the treatment of viral infection

Publications (1)

Publication Number Publication Date
KR20240009918A true KR20240009918A (ko) 2024-01-23

Family

ID=82931820

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031854A Pending KR20240009918A (ko) 2021-02-22 2022-02-22 바이러스 감염 치료를 위한 rock2 억제제

Country Status (8)

Country Link
US (1) US20240165116A1 (https=)
EP (1) EP4301132A4 (https=)
JP (1) JP2024507414A (https=)
KR (1) KR20240009918A (https=)
CN (1) CN117529320A (https=)
AU (1) AU2022224669A1 (https=)
CA (1) CA3209240A1 (https=)
WO (1) WO2022178420A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
EP4393917A4 (en) * 2021-09-18 2025-09-10 Beijing Tide Pharmaceutical Co Ltd SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF
CN121368592A (zh) * 2023-04-18 2026-01-20 盖诺斯克公司 Rock2蛋白激酶的血脑屏障穿透性选择性抑制剂及其用途
AU2024256326A1 (en) * 2023-04-18 2025-11-27 Genosco Inc. Selective inhibitors of rock2 protein kinases and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470137A (en) * 1967-02-14 1969-09-30 Du Pont Inter se copolymers of bicyclo(1.1.0)butanes
JP6593305B2 (ja) * 2016-11-09 2019-10-23 株式会社村田製作所 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器
JP7311228B2 (ja) * 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
EP3992183A4 (en) * 2019-06-25 2023-06-21 Beijing Tide Pharmaceutical Co., Ltd. METHODS OF TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
KR20230061444A (ko) * 2020-08-31 2023-05-08 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Rho-연관 단백질 인산화효소 억제제의 염, 염의 고체 형태, 이의 제조 방법 및 이의 용도
EP4393917A4 (en) * 2021-09-18 2025-09-10 Beijing Tide Pharmaceutical Co Ltd SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF
CN118215468A (zh) * 2021-11-16 2024-06-18 北京泰德制药股份有限公司 一种rock2抑制剂的纳米晶制剂及其制备方法

Also Published As

Publication number Publication date
CA3209240A1 (en) 2022-08-25
EP4301132A1 (en) 2024-01-10
JP2024507414A (ja) 2024-02-19
EP4301132A4 (en) 2025-03-26
WO2022178420A1 (en) 2022-08-25
AU2022224669A1 (en) 2023-09-28
CN117529320A (zh) 2024-02-06
US20240165116A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR20240009918A (ko) 바이러스 감염 치료를 위한 rock2 억제제
JP5918848B2 (ja) ベンゾチアゾール化合物およびその薬学的使用
CN101990434B (zh) 用于治疗沙粒病毒感染的抗病毒药物
AU2012321106B2 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
JP6591530B2 (ja) 有機化合物
US20040224916A1 (en) Compositions and methods for combination antiviral therapy
EP3848026A1 (en) Combinations and methods comprising a capsid assembly inhibitor
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
TW202203917A (zh) 治療細胞激素釋放症候群之方法
JP2019011343A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2021501178A (ja) 虚血性脳卒中の治療のための芳香族スルホンアミド誘導体
WO2020016427A1 (en) Inhibitors of hepatitis b virus
FI120403B (fi) 4-(2-amino-6-(syklopropyyliamino)-9H-purin-9-yyli)-2-syklopenteeni-1-metanoli-sukkinaatti viruksia torjuvana aineena
CN121843949A (zh) 用于治疗病毒感染的化合物和方法
US20190070212A1 (en) Compounds and compositions for the treatment of infections
US20260007673A1 (en) Rock2 inhibitors for the treatment of viral infections
JP2014532636A (ja) ウイルス感染の処置のためのヌクレオシドアナログおよび該処置に対する感受性を評価するための方法
US11247996B2 (en) Small molecule inhibitors for transcription factors
EP2258364A1 (en) Preventive and/or remedy for vascular diseases
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
US8815878B1 (en) Spiro hemiaminals for treating viral diseases
HK40031991A (en) Methods of treating and preventing graft versus host disease
JPH0551566B2 (https=)
JPH0551567B2 (https=)
HK40006418A (en) Combinations and methods comprising a capsid assembly inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230918

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250220

Comment text: Request for Examination of Application